LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Price, Quote, News and Overview
NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD
LCTX Quote, Performance and Key Statistics
0.4
-0.01 (-2.44%)
The current stock price of LCTX is 0.4 USD. In the past month the price decreased by -21.03%. In the past year, price decreased by -64.91%.
LCTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About LCTX
Company Profile
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Company Info
LINEAGE CELL THERAPEUTICS IN
2173 Salk Avenue, Suite 200
Carlsbad CALIFORNIA 92008 US
CEO: Brian M. Culley
Employees: 72
Company Website: https://lineagecell.com/
Investor Relations: https://investor.lineagecell.com
Phone: 15105213390
LINEAGE CELL THERAPEUTICS IN / LCTX FAQ
What is the stock price of LINEAGE CELL THERAPEUTICS IN today?
The current stock price of LCTX is 0.4 USD. The price decreased by -2.44% in the last trading session.
What is the ticker symbol for LINEAGE CELL THERAPEUTICS IN stock?
The exchange symbol of LINEAGE CELL THERAPEUTICS IN is LCTX and it is listed on the NYSE Arca exchange.
On which exchange is LCTX stock listed?
LCTX stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for LINEAGE CELL THERAPEUTICS IN stock?
13 analysts have analysed LCTX and the average price target is 4.25 USD. This implies a price increase of 962.51% is expected in the next year compared to the current price of 0.4. Check the LINEAGE CELL THERAPEUTICS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LINEAGE CELL THERAPEUTICS IN worth?
LINEAGE CELL THERAPEUTICS IN (LCTX) has a market capitalization of 91.34M USD. This makes LCTX a Micro Cap stock.
How many employees does LINEAGE CELL THERAPEUTICS IN have?
LINEAGE CELL THERAPEUTICS IN (LCTX) currently has 72 employees.
What are the support and resistance levels for LINEAGE CELL THERAPEUTICS IN (LCTX) stock?
LINEAGE CELL THERAPEUTICS IN (LCTX) has a resistance level at 0.44. Check the full technical report for a detailed analysis of LCTX support and resistance levels.
Is LINEAGE CELL THERAPEUTICS IN (LCTX) expected to grow?
The Revenue of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to grow by 41.15% in the next year. Check the estimates tab for more information on the LCTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LINEAGE CELL THERAPEUTICS IN (LCTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LCTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LCTX, evaluating the profitability, health, valuation and growth aspects
- LINEAGE CELL THERAPEUTICS IN (LCTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LINEAGE CELL THERAPEUTICS IN (LCTX) Sales and EPS estimates to see what analysts future expectations are.
- LINEAGE CELL THERAPEUTICS IN (LCTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LINEAGE CELL THERAPEUTICS IN (LCTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Chart to make your own analysis
- LINEAGE CELL THERAPEUTICS IN (LCTX) Latest news and press-releases to stay up to date.
Does LINEAGE CELL THERAPEUTICS IN (LCTX) stock pay dividends?
LCTX does not pay a dividend.
When does LINEAGE CELL THERAPEUTICS IN (LCTX) report earnings?
LINEAGE CELL THERAPEUTICS IN (LCTX) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of LINEAGE CELL THERAPEUTICS IN (LCTX)?
LINEAGE CELL THERAPEUTICS IN (LCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).
What is the Short Interest ratio of LINEAGE CELL THERAPEUTICS IN (LCTX) stock?
The outstanding short interest for LINEAGE CELL THERAPEUTICS IN (LCTX) is 10.02% of its float. Check the ownership tab for more information on the LCTX short interest.
LCTX Technical Analysis
LCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LCTX. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
LCTX Financial Highlights
Over the last trailing twelve months LCTX reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 23.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.44% | ||
| ROE | -23.74% | ||
| Debt/Equity | 0 |
LCTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to LCTX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.9% and a revenue growth 41.15% for LCTX